Project Grant R21AI187886
Award Date 8/13/25
Completion Date 7/31/27
Dollars Obligated $224K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
North Carolina, USA
Similar Awards
- This $197,366 Project Grant was awarded on March 1, 2025 by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The project aims to identify the molecular mechanisms that control the natural, immune-mediated restriction of X4-tropic HIV virus, which typically emerges only in late-stage HIV disease when the immune system is impaired. The research will utilize primary CD4 T cells, in vivo analyses in...
- The federal Project Grant award of $3,436,588.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The award supports research to investigate the role of the TLE3 transcription cofactor in regulating the function and persistence of CD8+ T cells during chronic viral infections and cancer. The research aims to molecularly reconstruct the T cell exhaustion process and identify therapeutic...
- This $624,902 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to investigate the impact of the HIV accessory protein Vpr on epigenetic remodeling and viral persistence in myeloid cells. The 5-year project, starting on Apr 23, 2025, will focus on characterizing how Vpr induces epigenetic changes to facilitate sustained HIV transcription and latency reactivation, as well as...
- This $118,488 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) on January 20, 2025, supports research to develop HIV-resistant hematopoietic stem cells through targeted base editing. The project aims to identify genetic mutations in the CCR5 and CXCR4 co-receptors that can prevent HIV entry into CD4 cells while maintaining the central functions of these proteins in hematopoiesis. The research involves...
- This Project Grant award of $285,816 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) will support research to enhance understanding of ADP-ribosylation (ADPR) and its role in HIV-1 latency and reactivation. The awardee, The Regents of the University of California, San Francisco, will conduct biochemical, proteomic, and cellular assays to identify global proteomic changes to ADPR during HIV-1 latency and reactivation,...
- This federal Project Grant award of $848,839 from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research to uncover new mechanisms by which HIV accessory proteins control natural killer (NK) cell function. The research aims to identify new NK cell ligands regulated by HIV infection and examine how changes to HIV accessory proteins like Nef and Vif impact the "missing self" trigger that drives NK cell...
- This $131,268 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) supports research at George Washington University to evaluate protein tyrosine phosphatases PTPN1 and PTPN2 as targets for improving natural killer (NK) cell function against HIV. The goal is to boost the cytotoxicity of effector lymphocytes, including NK cells, which are critical for controlling HIV infection but become dysfunctional due to...
- This $109,671 Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) aims to characterize the mechanisms by which HIV-infected macrophages evade natural killer (NK) cell-mediated killing. The central hypothesis is that HIV-infected macrophages resist NK cell-mediated killing by reducing NK cell lytic function and antagonizing death receptor signaling. The specific aims are to: 1) Characterize the release of...
- This $108,115 Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855), supports comprehensive characterization of lentiviral vector (LVV) integration and impact on host cell biology using novel genomic technologies. The research aims to provide a deeper understanding of LVV integration patterns and cellular transformation, which has emerged as a critical safety...
- This $769,414 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support research on how the cellular protein SAMHD1 regulates HIV-1 innate immunity and viral gene expression in primary macrophages. The long-term goal is to define the functional roles and molecular mechanisms of SAMHD1 in regulating innate immunity during persistent HIV-1 infection of macrophages. The research...